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A B S T R A C T
Background: The brain's major inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and the brain-
derived neurotrophic factor (BDNF) play important roles in several stress-related disorders. Magnetic reso-
nance spectroscopy (MRS) allows for non-invasive quantification of GABA concentration in the brain. We
investigated the relationship between GABA concentration in the left dorsolateral prefrontal cortex (DLPFC) and
BDNF concentration in the serum in a community-based sample of young subjects.
Methods: For the GABA measurement a single voxel MR spectrum was assessed in the prefrontal lobe (25  40 
30 mm) using the MEGA-PRESS method in 276 subjects. BDNF serum concentrations were assessed with an ELISA
kit. For 147 subjects we had both MRS and BDNF serum data, and for 79 subjects we had genotype data on the
BDNF rs6265 polymorphism. Depressive psychopathology was assessed using Beck's Depression Inventory (BDI),
Montgomery-Asberg Depression Rating Scale (MADRS) and Structured Clinical Interviews for Diagnostic and
Statistical Manual of Mental Disorders (SCID) for DSM-IV.
Results: GABA concentration in the left DLPFC was negatively associated with BDNF serum concentration (r ¼
-.264, p ¼ .001). This correlation remained significant if corrected for sex (r ¼ -.264, p ¼ .001). BDNF serum
concentration was also positively associated with volumes and surface areas of the left prefrontal cortex (p ¼ .048,
p ¼ .005). There were no significant associations or interaction with depressive psychopathology (BDI, MADRS,
SCID) or rs6265.
Conclusion: The results of this study suggest that GABA, BDNF and prefrontal brain volumes are interrelated, but
do not show a strong association to depressive psychopathology, possibly due to the mild forms of psychiatric
conditions present in our community-based sample.
1. Introduction
There is growing evidence that the inhibitory neurotransmitter
gamma-aminobutyric acid (GABA) and the brain-derived neurotrophic
factor (BDNF) play crucial roles in depression, anxiety, epilepsy, and in
the treatment of these conditions (Butler et al., 2018; Gabbay et al., 2017;
Hasler, van der Veen, Grillon, Drevets and Shen, 2010; Helms et al.,
2006; Long et al., 2013; Moreira et al., 2019; Sanacora et al., 2012).
GABA is the primary inhibitory neurotransmitter in the adult brain
and shapes the dynamic neural network via GABAergic interneurons
(Fukuchi et al., 2014; Schur et al., 2016). Magnetic resonance spectros-
copy (MRS) allows for a non-invasive measurement of the GABA
concentration in the brain of living humans. Human and rat studies
showed gender-related differences in GABA concentration, with men
showing higher GABA concentrations compared to women (Al-Suwailem
et al., 2018; Kirkovski et al., 2018; O'Gorman et al., 2011; Pandya et al.,
2019).
MRS is an imaging technique to quantify metabolites such as GABA in
the brain within one or several voxels of interest (Egerton et al., 2017;
Lener et al., 2017; Long et al., 2013). With MRS, signals from total intra-
and extracellular GABA as well as GABAergic interneurons across all
tissue content are measured (Egerton et al., 2017; Schur et al., 2016). The
MRS-visible GABA signal therefore reflects the dynamic balance between
GABA synthesis, reuptake and degradation around the synapses (Hasler
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et al., 2010), and has been shown to be sensitive to medication-induced
changes (e.g. from antiepileptic drugs like topiramate (Kuzniecky et al.,
2002; Reis et al., 2002), which also induce changes in cortical excitability
in humans (Dyke et al., 2017).
BDNF is a protein that belongs to the neurotrophin family of growth
factors and it is involved in several aspects of neuronal functioning
(Naegelin et al., 2018). BDNF can be found in the brain as well as in the
blood, secreted by circulating platelets in humans, which release BDNF
during blood coagulation. Its concentration can be measured
non-invasively in serum (Lommatzsch et al., 2005; Yamamoto and Gur-
ney, 1990). BDNF serum concentrations have been associated with the
BDNF concentration within the brain (Karege et al., 2002; Klein et al.,
2011). However, the mechanisms explaining this association remain to
be fully elucidated (de Azevedo Cardoso et al., 2014; Karege et al., 2002;
Naegelin et al., 2018; Vinberg et al., 2013).
The most plausible explanation for the presence of BDNF in the
platelets are the platelet-generating megakaryocyte cells. These cells
have been found to contain BDNF transcripts and may represent the link
between brain and serum BDNF concentrations (Chacon-Fernandez et al.,
2016; Naegelin et al., 2018). BDNF serum concentrations were shown to
be decreased in untreated depressed participants compared to healthy
subjects, and females tend to have lower BDNF serum concentrations
compared to men (de Azevedo Cardoso et al., 2014; Elfving et al., 2012;
Ellsworth et al., 2013; Kreinin et al., 2015; Lommatzsch et al., 2005;
Molendijk et al., 2014; Ozan et al., 2010). Studies also found associations
between BDNF and the volume of the prefrontal cortex (Forde et al.,
2014; Frodl et al., 2008; Harrisberger et al., 2015; Matsuo et al., 2009;
Pezawas et al., 2004), suggesting a link between prefrontal brain struc-
ture and function, and BDNF concentration in the serum.
Some rat and human studies have demonstrated interactions between
GABA-ergic neurotransmission and BDNF release. On one hand, BDNF
can suppress or presynaptically enhance GABA release through the
activation of postsynaptic tropomyosin receptor kinase B (TrkB)-type
receptors, which may result in an altered total GABA concentration
(Bulleit and Hsieh, 2000; Colino-Oliveira et al., 2016; Kim et al., 2017;
Pezet et al., 2002; Tanaka et al., 1997; Wardle and Poo, 2003).
Conversely, changes in the balance between excitatory glutamatergic and
inhibitory GABAergic neurotransmission has been shown to alter BDNF
expression (Saffarpour et al., 2017). The activation of glutamate re-
ceptors enhances the synthesis of BDNF, whereas stimulation of the
GABAergic system decreases BDNF synthesis and thus may alter BDNF
concentration in the brain and in the blood (Fukuchi et al., 2014; Mar-
migere et al., 2003; Zafra et al., 1991).
Diminished GABA-ergic transmission in the prefrontal cortex has
been related to circuit dysfunction in mood- and stress-related disorders
including major depressive disorder (MDD) (Gerner et al., 1984; Ghosal
et al., 2017; Hasler et al., 2010). Given the results from rat and human
studies cited above, we hypothesized that a higher left dorsolateral
prefrontal cortex (DLPFC) GABA concentration is associated with lower
BDNF serum concentration, and that this association differs between
genders. To elucidate this putatively inverse relationship between GABA
and BDNF in healthy and depressed subjects, we investigated healthy
subjects and current and remitted MDD patients in a community-based
sample. In particular, we assessed left prefrontal GABA concentrations
with single-voxel MRS and BDNF concentration in the serum. Clinical
characterization of the research subjects included diagnostic interviews
based on DSM-IV and standard rating instruments for depressive
symptoms.
2. Methods and materials
2.1. Recruitment
Participants were recruited by advertisements in local newspapers or
by blackboard webpages of the University of Zurich for this ongoing
cohort study. This provided us with a sample of young adults from the
general population. After a full explanation of the goals and risks of the
study and after giving their consent, participants were admitted to the
study. Inclusion criteria were age between 18 and 40 years and prefer-
ably being without any psychopharmacological medication for the last
three months before testing to minimize the possible effects on the brain.
Participants with current or remitted MDD were included into the study,
but other severe psychiatric disorders, for example schizophrenia were
excluded. The local ethics committee approved the study and the written
consent (Kantonale Ethikkomission Zürich). The study described has
been carried out in accordance with the Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments involving
humans. In one of our previous studies (Hasler et al., 2019) we report
data from a subset of the participants in the present study.
2.2. Procedure
After giving consent the participants were screened for magnetic
resonance (MR) safety with a standard checklist and for psychological
disorders with the screening part of the Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders (SCID) for DSM-IV.
Later the participants completed an extensive battery of psychological
and physiological questionnaires. Validated German versions of all in-
struments were used. Finally, an approximately five hour long face-to-
face session at the Children's Hospital in Zurich was conducted.
The face-to-face session, during which participants had to complete
paper-pencil versions of psychological questionnaires, was supervised by
a trained psychologist. Fifty ml blood samples were collected by trained
staff from the hospital after the psychological assessments. Subjects un-
derwent an MR session in a 3.0T GE Discovery MR750 scanner.
2.3. Sample
276 subjects were assessed with MRS, in 147 we had both MRS and
BDNF serum data (67.6% females) and in 79 we also had genotype data
on the polymorphism rs6265 of the BDNF gene.
Exclusion criteria were age outside the range of 18–40 years, pref-
erably no use of psychopharmacological drugs in the past three months,
severe psychiatric disorders such as schizophrenia, drug or alcohol abuse
or and any illnesses or accidents affecting the brain or genetic variance,
as for example brain injuries or diabetes.
Of the 276 subjects who underwent magnetic resonance imaging
(MRI) scanning, two were excluded because they had mild abnormalities
that could potentially influence the results (an arachnoid cyst in the right
posterior lateral ventricle; a lipoma with dysplasia of the corpus cal-
losum) leaving us with a sample of 274 subjects. Of these 274 subjects, 75
were diagnosed with MDD (16 currently depressed and 59 partially or
fully remitted). Out of the reported 147 subjects with both GABA and
BDNF serum data, 29 were diagnosed with MDD, including eight
currently depressed and 21 partially or fully remitted (Table 1). Three of
the MDD cases were on psychotropic medication (antidepressants or
antipsychotics). Out of the 147 subjects, 99 were females and 54 of them
were taking contraceptive medication.
2.4. Blood sampling
Venous blood samples were taken on the day of MR scanning in the
Children's Hospital (mean time 2:12 p.m., standard deviation 1.1 h). The
blood samples were analysed by specialized laboratories in Basel
(Switzerland) and New York (United States).
BDNF serum samples were stored at 80 C before assaying BDNF
content. An enzyme-linked immunosorbent assay (ELISA) kit (Biosensis®
Mature BDNF RapidTM ELISA Kit: Human, Mouse, Rat; Thebarton, SA,
Australia) was used to assess the serum BDNF concentrations. Serum
samples were appropriately diluted (1:100) and detection of BDNF was
carried out on a pre-coated mouse monoclonal anti-mature BDNF 96-well
plate as described in the manufacturer's protocol. The absorbance was
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measured within 5 min after addition of the stop solution in a microplate
reader set at 450nm and a correction wavelength set to 690nm, to
determine BDNF concentrations according to the standard curve. All
assays were carried out in duplicate and means were calculated.
2.5. MRI data acquisition and analyses
MRI data were obtained with a 3.0 GE Discovery MR750 scanner
equipped with an eight-channel receive-only head coil. The measure-
ments included a localizer and a 3D T1-weighted spoiled gradient
recalled (SPGR) sequence for the assessment of global and local brain
volumes (162 slices of 256 x 256 voxels, 1  1  1 mm resolution; TR ¼
11 ms, TE ¼ 5 ms, TI ¼ 600 ms, flip angle 8), which was used for the
localization of the MR spectra.
T1-weighted images were segmented and warped into MNI space
using “new segment” procedure in SPM12 for Matlab. For volumetric
measurements, freesurfer (version 5.3.0) was run over the 3-dimensional
T1-weighted images (Dale et al., 1999; Fischl et al., 1999). Volumes of
subcortical structures, whole brain volumes and areas and thicknesses of
neocortical areas can be analysed by this software.
MR spectra were acquired from a 25  40  30 mm voxel in the left
frontal lobe using the MEGA-PRESS method (TE ¼ 69 ms, TR¼ 2000 ms,
320 averages and eight-step phase cycle; Figure 1). We chose the left
DLPFC (and not the right one) because most MRS studies examined the
left side (Moriguchi et al., 2018), and because of the default direction of
the chemical shift effect on the scanner, which by results in fat being
shifted to the left (so for a voxel on the left side of the brain, scalp fat is
shifted away from the voxel), and water being shifted to the right (so for a
voxel on the left side of the brain, ventricular water is also shifted away
from the voxel). Due to the major overlapping signals for GABA with
those from N-acetyl aspartate (NAA) and Creatine, the MEGA-PRESS
technique was used to edit the GABA signal (Schur et al., 2016). Due
to the overlap of the edited GABA peak with co-edited macromolecules,
findings represent GABAþ rather than pure GABA values.
MR spectra were preprocessed with a vendor-provided pipeline,
which included steps for coil combination, frequency alignment, phasing,
residual water removal, and averaging, and both the edited data and
water reference data were saved as.RAW files for processing with
LCModel. Spectral fitting for the edited data was performed with
LCModel version 6.3 using a simulated basis set, including basis spectra
for GABA, Glutamate, Glutamine, Glutathione, N-acetyl-aspartate (NAA),
and N-acetyl-aspartly-glutamate (NAAG). The control parameter sptype
was set to ‘mega-press-2’ to control the baseline fitting, and spectra were
visually inspected for the quality of the GABA fit.
Metabolite levels with a Cramer-Rao lower bound (CRLB) of more
than 20% were excluded from the analysis. Water-scaled GABAþ
Table 1. Clinical characteristics of the original sample (N ¼ 274) and the subsample (N ¼ 147) with available data concerning GABA concentration and BDNF serum
concentration used in this study.
GABA sample GABA-BDNF subsample
N 274 147
Age Mean (SD) [years] 24.68 (4.57) 24.45 (4.35)
Females 179 (65.3%) 99 (67.3%)
MDD current or remitted (N) 75 (27.4%) 29 (19.7%)
Medicated Subjects 3 (1.1%) 2 (1.4%)
Mean BDNF serum concentration (pg/ml) - 11500 (3400)
BDNF rs6265 genotypes (subsample N ¼ 109/79) c/c 61 c/t 43 t/t 5 c/c 43 c/t 33 t/t 3
BDI Mean (SD) 4.81 (6.87), 2 missing 3.81 (6.53), 2 missing
MADRS Mean (SD) 3.44 (5.56), 1 missing 2.96 (5.90), 1 missing
Volume left prefrontal cortex (gyri and sulci, cm3) 52.84 (6.10), 1 missing 53.18 (6.17)
Surface left prefrontal cortex (gyri and sulci, cm2) 165.16 (17.95), 1 missing 165.71 (17.33)
Figure 1. MR images showing the position of the measured voxel in the left DLPFC.
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concentrations were calculated in institutional units after correcting the
GABAþ and estimated water concentrations for cerebrospinal fluid
contamination (atrophy) within the voxel (Chowdhury et al., 2015).
Figure 2 shows the edited and unedited spectra for all participants,
together with the group mean spectra and the mean LCModel fit across
the group.
2.6. Psychological measurements
Subjects filled out the Becks Depression Inventory (BDI) (Beck et al.,
1961) and the Montgomery-Asberg Depression Rating Scale (MADRS)
(Montgomery and Asberg, 1979) shortly before MR scanning at the
Children's Hospital in Zurich, using the validated German versions.
Psychiatric diagnoses were made based on the SCID for DSM-IV (First
et al., 2001).
2.7. Statistics
In explorative analyses, we tested associations between GABAþ
concentration, biological measures (BDNF serum concentrations and left
DLPFC volumes) and depressive psychopathology (BDI, MADRS, MDD
DSM-IV diagnosis) using Pearson's bivariate correlation analyses in SPSS
(IBM SPSS Statistics, Version 24).
Due to previously reported gender differences concerning both GABA
and BDNF serum concentrations we repeated the analyses in the female
and male subsample. MDD was added to the analyses as confounding
parameter in a partial correlation. Post-hoc analyses were also conducted
to examine the link between BDNF and other neuro-metabolites present
in the edit OFF spectra, namely, NAA, Creatine, Choline, and myo-
inositol.
3. Results
Figure 3 shows that GABAþ concentration in the DLPFC was signif-
icantly negatively associated with the BDNF serum concentration (r ¼
-.264, p ¼ .001, N ¼ 147; Figure 3). This negative association was sig-
nificant in the female subsample (r ¼ -.306, p ¼ .002, N ¼ 99) but not in
the male subsample (r ¼ -.189, p ¼ .197, N ¼ 48).
BDNF serum concentrations were positively associated with the vol-
umes of the left prefrontal cortex (gyri and sulci; r ¼ .164, p ¼ .048, N ¼
147), and the surface area of the left prefrontal cortex (gyri and sulci; r ¼
.231, p ¼ .005, N ¼ 147). GABAþ concentration showed no significant
association with the volume or the surface of the left prefrontal cortex
(volume: r ¼ -.128, p ¼ .122; surface: r ¼ -.089, p ¼ .282; N ¼ 147).
GABAþ concentration in the left DLPFC was not significantly asso-
ciated with the diagnosis of MDD (r¼ -.092, p¼ .268, N¼ 147), BDI sum
score (r ¼ -.043, p ¼ .604, N ¼ 145) and MADRS total score (r ¼ -.081, p
¼ .333, N ¼ 146, 1 missing). There was no significant association be-
tween BDNF concentration in the serum and MDD diagnosis (r ¼ .105, p
¼ .203, N ¼ 147), BDI sum score (r ¼ -.031, p ¼ 709, N ¼ 145) and
MADRS total score (r ¼ .099, p ¼ .236, N ¼ 146). BDNF concentration in
the serum was not significantly associated with hippocampal volumes
(left hippocampus volume: r ¼ -.058, p ¼ .488; right hippocampus vol-
ume: r ¼ .041, p ¼ .618; N ¼ 147). In N ¼ 79 subjects we had genotype
data on the BDNF polymorphism rs6265. We did not find a significant
association between this polymorphism and bilateral hippocampal brain
volumes (left hippocampus volume: r ¼ .159, p ¼ .161; right hippo-
campus volume: r ¼ .170, p ¼ .135; N ¼ 79), BDNF serum concentration
(r ¼ .059, p ¼ .608, N ¼ 79) or prefrontal GABAþ concentration (r ¼
-.038, p¼ .742, N¼ 79). This result remained unchanged after excluding
the three medicated subjects (data not shown). Using age, BMI or sports
activity as a control variable did not change the results either.
The bivariate correlations were also calculated for genders separately,
due to reported sex-differences in GABA and BDNF systems. There was a
trend for an association between left DLPFC GABAþ concentration and
MADRS total score in male subjects (r ¼ -.267, p ¼ .067, N ¼ 48) but not
in female subjects (r ¼ -.010, p ¼ .922, N ¼ 98). The partial correlation
showed a significant association between prefrontal GABAþ and BDNF
serum concentration if corrected for sex (r ¼ -.264, p ¼ .001).
The partial correlation revealed that MDD did not change the sig-
nificant results between GABAþ and BDNF serum concentration (r ¼
-.257, p¼ .002, N¼ 144), between BDNF concentration in the serum and
left prefrontal volume and surface-area (volume: r ¼ .197, p ¼ .017;
surface-area: r ¼ .266, p¼ .001; N ¼ 144). The use of contraceptives was
not associatedwith the BDNF polymorphism (r¼ .032, p¼ .780, N¼ 79),
BDNF serum concentration (r ¼ .097, p ¼ .241, N ¼ 147) and prefrontal
GABAþ concentration (r ¼ -.053, p ¼ .525, N ¼ 147). The post-hoc tests
for a link between BDNF and other neuro-metabolites present in the edit
OFF spectra did not reveal any significant associations (all p > 0.12).
Using Creatinine instead of H2O as reference signal did not change the
main findings of this study.
4. Discussion
In a cohort of young adults from the general population, we investi-
gated the link between GABAþ levels in the left DLPFC, prefrontal brain
volumes and surface-areas, serum BDNF concentrations, and depressive
psychopathology.
Figure 2. Edited and unedited spectra for all participants. The individual spectra for all participants are shown in grey, with the group-mean spectra overlaid in black
and the mean LCModel fit overlaid in red. The residuals from each participant are also plotted in grey above the spectra.
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The main finding of the present study is that higher GABAþ con-
centrations in the left DLPFC were associated with lower BDNF serum
concentrations in young adults. No association was found between the
BDNF polymorphism and GABAþ concentration. In the gender-specific
analyses, the significant association between GABAþ and BDNF serum
concentration held true in the female but not in the male subsample.
BDNF serum concentration was associated with increased brain volumes
and surface-areas in the left prefrontal cortex. No associations were found
between GABAþ concentration, BDNF polymorphism and left prefrontal
volumes and surface-areas. Depressive symptoms as measured by BDI
and MADRS and MDD diagnosis were not associated with GABAþ, BDNF
polymorphism or BDNF serum concentrations, but we found a negative
trend towards a correlation between GABAþ concentration and MADRS
total score in males but not in females. Depression did not affect the
association between GABA and BDNF.
Previous studies investigating the relationship between GABA and
BDNF have suggested a complex and not yet fully understood interplay
between the two factors, as discussed in the introduction (Bulleit and
Hsieh, 2000; Colino-Oliveira et al., 2016; Marmigere et al., 2003; Pezet
et al., 2002; Saffarpour et al., 2017; Zafra et al., 1991). The connection
between GABA and BDNFmay depend on pre- and postsynaptic effects of
the two factors and may differ considerably between brain regions
(Marmigere et al., 2003; Saffarpour et al., 2017; Tanaka et al., 1997;
Zafra et al., 1991). Both GABA and BDNF serum concentrations have
been shown to be reduced in subjects with MDD and subjects after acute
and chronic stress (Fogaca and Duman, 2019; Hasler et al., 2010; Kishi
et al., 2017). However, in remitted subjects with MDD, prefrontal GABA
concentration was found to be normal (Hasler et al., 2005; Schur et al.,
2016). Our findings of normal BDNF and GABA concentrations in MDD
may therefore arise as a result of our community-based samplingmethod,
leading to the inclusion of subjects with rather mild, partly remitted and
unmedicated MDD.
Previous studies on serum BDNF concentrations have found gender
differences, with men showing higher BDNF serum concentrations
compared to women (de Azevedo Cardoso et al., 2014; Ozan et al., 2010).
Our study suggests that gender differences in BDNF concentrations are
unrelated to depression-related disorders, and could possibly be related
to the effects of sex hormones (Elfving et al., 2012).
To date, our knowledge about sex-related differences concerning the
GABAergic system is limited. Some studies have shown higher GABA
concentrations in men compared to women (O'Gorman et al., 2011;
Pandya et al., 2019). Our significant correlation between GABAþ and
BDNF serum concentration in the female but not in the male subsample
may reflect both GABA and BDNF specific gender differences. The
negative trend in our results between GABAþ concentrations and
MADRS scores in the male but not in the female subsample may also
reflect the gender differences concerning GABA but should be interpreted
with caution. Although many previous studies investigated GABA and
BDNF serum concentrations in subjects with psychiatric disorders, the
apparent gender differences in both GABAþ and BDNF seen in our study
of young adults from the general population indicates that gender should
also be considered in group comparisons of healthy samples with psy-
chiatric groups (Molendijk et al., 2014). In addition, since BDNF con-
centrations can be normalized by antidepressant treatment (Kreinin
et al., 2015), medication status should be taken into account to avoid
potential confounds from medication effects.
BDNF is strongly expressed in the limbic brain regions, hence many
studies have tested for associations between hippocampal volumes and
BDNF serum concentrations, yielding inconsistent results (Frodl et al.,
2014; Harrisberger et al., 2015). In our study, we did not find a signifi-
cant correlation between BDNF concentration in the serum or the BDNF
polymorphism rs6265 and hippocampal brain volumes.
With regard to the BDNF polymorphism, we did not find a significant
association with BDNF concentration in the serum. The BDNF gene is
located on chromosome 11p13 and encodes proBDNF, which generates
mature BDNF, which can be measured in plasma and serum (Elfving
et al., 2012). Most studies have researched the single nucleotide poly-
morphism (SNP) rs6265 (Val66Met) of the BDNF gene, but the associa-
tion between this polymorphism and BDNF serum concentrations show
divergent results and the mechanism has yet to be demonstrated in detail
(Karege et al., 2002; Kishi et al., 2017; Naegelin et al., 2018; Ozan et al.,
2010). The Met allele of the rs6265 polymorphism is thought to impair
the intracellular trafficking of proBDNF into the dendrites and vesicles,
thus this SNP seems to play an important role in the regulation of
extracellular BDNF concentrations (Kishi et al., 2017). A series of studies
have examined the SNP rs6265 regarding the risk of depression and
hippocampal volumes (Elfving et al., 2012). In healthy controls, homo-
zygous Val/Val carriers of the rs6265 polymorphism showed larger
hippocampal volumes compared to Met carriers (Hajek et al., 2012; Kishi
et al., 2017). However, Harrisberger et al. found no such association
between the rs6265 polymorphism and hippocampal volume in patients
with MDD (Harrisberger et al., 2015). Forde et al. showed that the BDNF
Figure 3. Bivariate correlation between GABA concentration in the left prefrontal cortex, corrected for atrophy and water scaling, and BDNF serum concentration,
normalized and averaged (r ¼ -.264, p ¼ .001, N ¼ 147).
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Val66Met polymorphism may not be as specific as previously supposed,
but may have a global effect on the cortical morphology in humans
(Forde et al., 2014). Matsuo et al. presented smaller DLPFC volumes in
Val/Met carriers as compared to the Val/Val subjects (Matsuo et al.,
2009). Our results of increased BDNF serum concentration being asso-
ciated with larger volumes and surface-areas in the prefrontal cortex in
young adults may reflect the association between BDNF polymorphism
and prefrontal brain volume, but still it remains unclear whether and
how BDNF serum concentration is linked to BDNF in the brain (Naegelin
et al., 2018).
Recently it has been suggested that, aside from platelet-generating
megakaryocytes, epigenetics may play an important role in the associa-
tion between BDNF serum and brain BDNF concentrations (Cha-
con-Fernandez et al., 2016; Chen and Chen, 2017; Mallei et al., 2015;
Naegelin et al., 2018). Mallei et al. showed that homozygous mice Met
carriers displayed repressive neuronal activation of BDNF and repressive
epigenetic changes in certain BDNF promoters, which is accompanied by
reduced transcription of BDNF promoters (Mallei et al., 2015).
Our non-significant results regarding serum BDNF concentration and
depression-related symptoms may indicate that the downregulation of
BDNF serum concentration may not be associated with healthy or mostly
remittedMDD participants, but may be specific to severeMDD and reflect
the complex molecular pathologies of psychiatric disorders (Guilloux
et al., 2012).
The present study provides insight into the association of prefrontal
GABA concentration, BDNF serum concentration, prefrontal brain vol-
umes, and depressive symptoms in a cohort of young adults from the
general population. The approach of a community-based sample of young
subjects should be considered a strength of the present study, as the
comparability to the general population is higher than in studies that
included severely depressed participants under psychopharmacological
drugs. To our knowledge, the association between prefrontal GABA and
BDNF serum concentration has not been examined in in humans,
although animal studies have suggested an important connection be-
tween central GABA concentration and BDNF. Furthermore, our study
was large enough to study the sexes separately. We sought to keep the
time of the blood and MRS measurements constant, because BDNF shows
a strong circadian variation (Begliuomini et al., 2008).
The following limitation of our study merits comment. MRS total
GABA signal was measured within a relatively large voxel. Our method
does not allow for discrimination between GABA concentrations of
different cell types. The spectral overlap between GABA and other me-
tabolites remain a challenging issue with MRS. We used the MEGA-
PRESS technique to address this limitation, but it is important to note
that some macromolecular contribution is likely to be present in the
GABA signal detected by MEGA-PRESS, and this signal should therefore
be regarded as GABAþ rather than as pure GABA.
In the present study, two specific aspects of BDNF, namely its con-
centration in the serum and the rs6265 polymorphisms were investi-
gated. The relationship between brain and serum BDNF has still to be
elucidated and thus the results should be considered with caution.
Although contraceptive medication does not seem to impact our results,
we cannot rule out the possibility that differences between females and
males are moderated by sex-hormones. As our sample consisted of young
subjects from the general population with low depression scores, our
results may differ from samples with current MDD subjects.
In conclusion, our data suggest a complex but important association
between GABAþ concentration and BDNF serum concentration, pre-
frontal brain volumes and possible gender related differences in young
adults. To understand the mechanisms concerning the interaction be-
tween BDNF and GABA concentration better, it would be interesting to
combine the factors investigated in this study with stress-related epige-
netics in a bigger sample. We are planning to conduct follow-up assess-
ments of our cohort to evaluate the predictive value of our measures. For
the gender differences concerning GABA and BDNF concentration future
studies should focus on gender-matching between groups and should
consider the menstrual cycle, contraceptive use and sex-hormones of
female participants. In addition, in future studies it would be interesting
to examine the effects of neurotrophic factors and epigenetic markers and
their influence on depression and stress-related disorders.
Declarations
Author contribution statement
Sabrina Theresia Müller, Christopher Ritter: Performed the experi-
ments; Analyzed and interpreted the data; Wrote the paper.
Andreas Buchmann, Carmen Ghisleni: Performed the experiments;
Wrote the paper.
Melanie Haynes, Gregor Hasler: Conceived and designed the experi-
ments; Wrote the paper.
Ruth Tuura: Conceived and designed the experiments; Contributed
reagents, materials, analysis tools or data; Wrote the paper.
Funding statement
This work was supported by the University of Bern, Switzerland, and
the University Children’s Hospital Zurich, Switzerland.
Competing interest statement
The authors declare no conflict of interest.
Additional information
No additional information is available for this paper.
Acknowledgements
We are grateful to all the participants who took part in this study. We
thank Fabia Colombo, Isabelle Fischer and Sarela Brechbühl for data
acquisition and data entry. We would like to express our gratitude to
Steffen Bollmann and Yosuke Morishima for their highly valued support
in the technical setup of the study.
References
Al-Suwailem, E., Abdi, S., El-Ansary, A., 2018. Sex differences in the glutamate signaling
pathway in juvenile rats. J. Neurosci. Res. 96 (3), 459–466.
Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for
measuring depression. Arch. Gen. Psychiatr. 4, 561–571.
Begliuomini, S., Lenzi, E., Ninni, F., Casarosa, E., Merlini, S., Pluchino, N.,
Genazzani, A.R., 2008. Plasma brain-derived neurotrophic factor daily variations in
men: correlation with cortisol circadian rhythm. J. Endocrinol. 197 (2), 429–435.
Bulleit, R.F., Hsieh, T., 2000. MEK inhibitors block BDNF-dependent and -independent
expression of GABA(A) receptor subunit mRNAs in cultured mouse cerebellar granule
neurons. Brain Res. Dev. Brain Res. 119 (1), 1–10.
Butler, K.M., Moody, O.A., Schuler, E., Coryell, J., Alexander, J.J., Jenkins, A., Escayg, A.,
2018. De novo variants in GABRA2 and GABRA5 alter receptor function and
contribute to early-onset epilepsy. Brain 141 (8), 2392–2405.
Chacon-Fernandez, P., Sauberli, K., Colzani, M., Moreau, T., Ghevaert, C., Barde, Y.A.,
2016. Brain-derived neurotrophic factor in megakaryocytes. J. Biol. Chem. 291 (19),
9872–9881.
Chen, K.W., Chen, L., 2017. Epigenetic regulation of BDNF gene during development and
diseases. Int. J. Mol. Sci. 18 (3).
Chowdhury, F.A., O'Gorman, R.L., Nashef, L., Elwes, R.D., Edden, R.A., Murdoch, J.B.,
Richardson, M.P., 2015. Investigation of glutamine and GABA levels in patients with
idiopathic generalized epilepsy using MEGAPRESS. J. Magn. Reson. Imag. 41 (3),
694–699.
Colino-Oliveira, M., Rombo, D.M., Dias, R.B., Ribeiro, J.A., Sebastiao, A.M., 2016. BDNF-
induced presynaptic facilitation of GABAergic transmission in the hippocampus of
young adults is dependent of TrkB and adenosine A2A receptors. Purinergic Signal.
12 (2), 283–294.
Dale, A.M., Fischl, B., Sereno, M.I., 1999. Cortical surface-based analysis. I. Segmentation
and surface reconstruction. Neuroimage 9 (2), 179–194.
de Azevedo Cardoso, T., Mondin, T.C., Wiener, C.D., Marques, M.B., Fucolo Bde, A.,
Pinheiro, R.T., Oses, J.P., 2014. Neurotrophic factors, clinical features and gender
differences in depression. Neurochem. Res. 39 (8), 1571–1578.
S.T. Müller et al. Heliyon 6 (2020) e04025
6
Dyke, K., Pepes, S.E., Chen, C., Kim, S., Sigurdsson, H.P., Draper, A., Jackson, S.R., 2017.
Comparing GABA-dependent physiological measures of inhibition with proton
magnetic resonance spectroscopy measurement of GABA using ultra-high-field MRI.
Neuroimage 152, 360–370.
Egerton, A., Modinos, G., Ferrera, D., McGuire, P., 2017. Neuroimaging studies of GABA
in schizophrenia: a systematic review with meta-analysis. Transl. Psychiatry 7 (6),
e1147.
Elfving, B., Buttenschon, H.N., Foldager, L., Poulsen, P.H., Andersen, J.H.,
Grynderup, M.B., Mors, O., 2012. Depression, the Val66Met polymorphism, age, and
gender influence the serum BDNF level. J. Psychiatr. Res. 46 (9), 1118–1125.
Ellsworth, K.A., Moon, I., Eckloff, B.W., Fridley, B.L., Jenkins, G.D., Batzler, A., Wang, L.,
2013. FKBP5 genetic variation: association with selective serotonin reuptake
inhibitor treatment outcomes in major depressive disorder. Pharmacogenetics
Genom. 23 (3), 156–166.
First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 2001. Structured Clinical
Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/
P). Biometrics Research, New York State Psychiatric Institute, New York.
Fischl, B., Sereno, M.I., Dale, A.M., 1999. Cortical surface-based analysis. II: inflation,
flattening, and a surface-based coordinate system. Neuroimage 9 (2), 195–207.
Fogaca, M.V., Duman, R.S., 2019. Cortical GABAergic dysfunction in stress and
depression: new insights for therapeutic interventions. Front. Cell. Neurosci. 13, 87.
Forde, N.J., Ronan, L., Suckling, J., Scanlon, C., Neary, S., Holleran, L., Cannon, D.M.,
2014. Structural neuroimaging correlates of allelic variation of the BDNF val66met
polymorphism. Neuroimage 90, 280–289.
Frodl, T., Carballedo, A., Frey, E.M., O'Keane, V., Skokauskas, N., Morris, D., Connor, T.,
2014. Expression of glucocorticoid inducible genes is associated with reductions in
cornu ammonis and dentate gyrus volumes in patients with major depressive
disorder. Dev. Psychopathol. 26 (4 Pt 2), 1209–1217.
Frodl, T., Moller, H.J., Meisenzahl, E., 2008. Neuroimaging genetics: new perspectives in
research on major depression? Acta Psychiatr. Scand. 118 (5), 363–372.
Fukuchi, M., Kirikoshi, Y., Mori, A., Eda, R., Ihara, D., Takasaki, I., Tsuda, M., 2014.
Excitatory GABA induces BDNF transcription via CRTC1 and phosphorylated CREB-
related pathways in immature cortical cells. J. Neurochem. 131 (2), 134–146.
Gabbay, V., Bradley, K.A., Mao, X., Ostrover, R., Kang, G., Shungu, D.C., 2017. Anterior
cingulate cortex gamma-aminobutyric acid deficits in youth with depression. Transl.
Psychiatry 7 (8), e1216.
Gerner, R.H., Fairbanks, L., Anderson, G.M., Young, J.G., Scheinin, M., Linnoila, M.,
Cohen, D.J., 1984. CSF neurochemistry in depressed, manic, and schizophrenic
patients compared with that of normal controls. Am. J. Psychiatr. 141 (12),
1533–1540.
Ghosal, S., Hare, B., Duman, R.S., 2017. Prefrontal cortex GABAergic deficits and circuit
dysfunction in the pathophysiology and treatment of chronic stress and depression.
Curr. Opin. Behav. Sci. 14, 1–8.
Guilloux, J.P., Douillard-Guilloux, G., Kota, R., Wang, X., Gardier, A.M., Martinowich, K.,
Sibille, E., 2012. Molecular evidence for BDNF- and GABA-related dysfunctions in the
amygdala of female subjects with major depression. Mol. Psychiatr. 17 (11),
1130–1142.
Hajek, T., Kopecek, M., Hoschl, C., 2012. Reduced hippocampal volumes in healthy
carriers of brain-derived neurotrophic factor Val66Met polymorphism: meta-analysis.
World J. Biol. Psychiatr. 13 (3), 178–187.
Harrisberger, F., Smieskova, R., Schmidt, A., Lenz, C., Walter, A., Wittfeld, K.,
Borgwardt, S., 2015. BDNF Val66Met polymorphism and hippocampal volume in
neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci.
Biobehav. Rev. 55, 107–118.
Hasler, G., Buchmann, A., Haynes, M., Müller, S., Ghisleni, C., Brechbühl, S., Tuura, R.,
2019. Association between prefrontal glutamine levels and neuroticism determined
using proton magnetic resonance spectroscopy. Transl. Psychiatry in press.
Hasler, G., Neumeister, A., van der Veen, J.W., Tumonis, T., Bain, E.E., Shen, J.,
Charney, D.S., 2005. Normal prefrontal gamma-aminobutyric acid levels in remitted
depressed subjects determined by proton magnetic resonance spectroscopy. Biol.
Psychiatr. 58 (12), 969–973.
Hasler, G., van der Veen, J.W., Grillon, C., Drevets, W.C., Shen, J., 2010. Effect of acute
psychological stress on prefrontal GABA concentration determined by proton
magnetic resonance spectroscopy. Am. J. Psychiatr. 167 (10), 1226–1231.
Helms, G., Ciumas, C., Kyaga, S., Savic, I., 2006. Increased thalamus levels of glutamate
and glutamine (Glx) in patients with idiopathic generalised epilepsy. J. Neurol.
Neurosurg. Psychiatry 77 (4), 489–494.
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J.M., 2002.
Decreased serum brain-derived neurotrophic factor levels in major depressed
patients. Psychiatr. Res. 109 (2), 143–148.
Kim, J., Lee, S., Kang, S., Kim, S.H., Kim, J.C., Yang, M., Moon, C., 2017. Brain-derived
neurotropic factor and GABAergic transmission in neurodegeneration and
neuroregeneration. Neural Regen. Res. 12 (10), 1733–1741.
Kirkovski, M., Suo, C., Enticott, P.G., Yucel, M., Fitzgerald, P.B., 2018. Short
communication: sex-linked differences in gamma-aminobutyric acid (GABA) are
related to social functioning in autism spectrum disorder. Psychiatry Res.
Neuroimaging. 274, 19–22.
Kishi, T., Yoshimura, R., Ikuta, T., Iwata, N., 2017. Brain-derived neurotrophic factor and
major depressive disorder: evidence from meta-analyses. Front. Psychiatr. 8, 308.
Klein, A.B., Williamson, R., Santini, M.A., Clemmensen, C., Ettrup, A., Rios, M., Aznar, S.,
2011. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int.
J. Neuropsychopharmacol. 14 (3), 347–353.
Kreinin, A., Lisson, S., Nesher, E., Schneider, J., Bergman, J., Farhat, K., Pinhasov, A.,
2015. Blood BDNF level is gender specific in severe depression. PLoS One 10 (5),
e0127643.
Kuzniecky, R., Ho, S., Pan, J., Martin, R., Gilliam, F., Faught, E., Hetherington, H., 2002.
Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy
adults. Neurology 58 (3), 368–372.
Lener, M.S., Niciu, M.J., Ballard, E.D., Park, M., Park, L.T., Nugent, A.C., Zarate Jr., C.A.,
2017. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of
major depression and antidepressant response to ketamine. Biol. Psychiatr. 81 (10),
886–897.
Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff-
Werner, P., Virchow, J.C., 2005. The impact of age, weight and gender on BDNF
levels in human platelets and plasma. Neurobiol. Aging 26 (1), 115–123.
Long, Z., Medlock, C., Dzemidzic, M., Shin, Y.W., Goddard, A.W., Dydak, U., 2013.
Decreased GABA levels in anterior cingulate cortex/medial prefrontal cortex in panic
disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 44, 131–135.
Mallei, A., Baj, G., Ieraci, A., Corna, S., Musazzi, L., Lee, F.S., Popoli, M., 2015. Expression
and dendritic trafficking of BDNF-6 splice variant are impaired in knock-in mice
carrying human BDNF Val66Met polymorphism. Int. J. Neuropsychopharmacol. 18
(12).
Marmigere, F., Rage, F., Tapia-Arancibia, L., 2003. GABA-glutamate interaction in the
control of BDNF expression in hypothalamic neurons. Neurochem. Int. 42 (4),
353–358.
Matsuo, K., Walss-Bass, C., Nery, F.G., Nicoletti, M.A., Hatch, J.P., Frey, B.N., Soares, J.C.,
2009. Neuronal correlates of brain-derived neurotrophic factor Val66Met
polymorphism and morphometric abnormalities in bipolar disorder.
Neuropsychopharmacology 34 (8), 1904–1913.
Molendijk, M.L., Spinhoven, P., Polak, M., Bus, B.A., Penninx, B.W., Elzinga, B.M., 2014.
Serum BDNF concentrations as peripheral manifestations of depression: evidence
from a systematic review and meta-analyses on 179 associations (N¼9484). Mol.
Psychiatr. 19 (7), 791–800.
Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to
change. Br. J. Psychiatry 134, 382–389.
Moreira, F.P., de Azevedo Cardoso, T., Mondin, T.C., Wiener, C.D., de Mattos Souza, L.D.,
Oses, J.P., da Silva, R.A., 2019. Serum level of nerve growth factor is a potential
biomarker of conversion to bipolar disorder in women with major depressive
disorder. Psychiatr. Clin. Neurosci.
Moriguchi, S., Takamiya, A., Noda, Y., Horita, N., Wada, M., Tsugawa, S., Nakajima, S.,
2018. Glutamatergic neurometabolite levels in major depressive disorder: a
systematic review and meta-analysis of proton magnetic resonance spectroscopy
studies. Mol. Psychiatr.
Naegelin, Y., Dingsdale, H., Sauberli, K., Schadelin, S., Kappos, L., Barde, Y.A., 2018.
Measuring and validating the levels of brain-derived neurotrophic factor in human
serum. eNeuro 5 (2).
O'Gorman, R.L., Michels, L., Edden, R.A., Murdoch, J.B., Martin, E., 2011. In vivo
detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender
effects. J. Magn. Reson. Imag. 33 (5), 1262–1267.
Ozan, E., Okur, H., Eker, C., Eker, O.D., Gonul, A.S., Akarsu, N., 2010. The effect of
depression, BDNF gene val66met polymorphism and gender on serum BDNF levels.
Brain Res. Bull. 81 (1), 61–65.
Pandya, M., Palpagama, T.H., Turner, C., Waldvogel, H.J., Faull, R.L., Kwakowsky, A.,
2019. Sex- and age-related changes in GABA signaling components in the human
cortex. Biol. Sex Differ. 10 (1), 5.
Pezawas, L., Verchinski, B.A., Mattay, V.S., Callicott, J.H., Kolachana, B.S., Straub, R.E.,
Weinberger, D.R., 2004. The brain-derived neurotrophic factor val66met
polymorphism and variation in human cortical morphology. J. Neurosci. 24 (45),
10099–10102.
Pezet, S., Cunningham, J., Patel, J., Grist, J., Gavazzi, I., Lever, I.J., Malcangio, M., 2002.
BDNF modulates sensory neuron synaptic activity by a facilitation of GABA
transmission in the dorsal horn. Mol. Cell. Neurosci. 21 (1), 51–62.
Reis, J., Tergau, F., Hamer, H.M., Muller, H.H., Knake, S., Fritsch, B., Rosenow, F., 2002.
Topiramate selectively decreases intracortical excitability in human motor cortex.
Epilepsia 43 (10), 1149–1156.
Saffarpour, S., Shaabani, M., Naghdi, N., Farahmandfar, M., Janzadeh, A.,
Nasirinezhad, F., 2017. In vivo evaluation of the hippocampal glutamate, GABA and
the BDNF levels associated with spatial memory performance in a rodent model of
neuropathic pain. Physiol. Behav. 175, 97–103.
Sanacora, G., Treccani, G., Popoli, M., 2012. Towards a glutamate hypothesis of
depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Neuropharmacology 62 (1), 63–77.
Schur, R.R., Draisma, L.W., Wijnen, J.P., Boks, M.P., Koevoets, M.G., Joels, M.,
Vinkers, C.H., 2016. Brain GABA levels across psychiatric disorders: a systematic
literature review and meta-analysis of (1) H-MRS studies. Hum. Brain Mapp. 37 (9),
3337–3352.
Tanaka, T., Saito, H., Matsuki, N., 1997. Inhibition of GABAA synaptic responses by brain-
derived neurotrophic factor (BDNF) in rat hippocampus. J. Neurosci. 17 (9),
2959–2966.
Vinberg, M., Bukh, J.D., Bennike, B., Kessing, L.V., 2013. Are variations in whole blood
BDNF level associated with the BDNF Val66Met polymorphism in patients with first
episode depression? Psychiatr. Res. 210 (1), 102–108.
Wardle, R.A., Poo, M.M., 2003. Brain-derived neurotrophic factor modulation of
GABAergic synapses by postsynaptic regulation of chloride transport. J. Neurosci. 23
(25), 8722–8732.
Yamamoto, H., Gurney, M.E., 1990. Human platelets contain brain-derived neurotrophic
factor. J. Neurosci. 10 (11), 3469–3478.
Zafra, F., Castren, E., Thoenen, H., Lindholm, D., 1991. Interplay between glutamate and
gamma-aminobutyric acid transmitter systems in the physiological regulation of
brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal
neurons. Proc. Natl. Acad. Sci. U. S. A. 88 (22), 10037–10041.
S.T. Müller et al. Heliyon 6 (2020) e04025
7
